Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 15/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | UBE2N | P61088 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19254586 | 0.88 | ADORA2B (0.41) | ADORA2BADORA3ADORA2AADORA1KDM4E | |
| SCHEMBL19254587 | 0.85 | ALDH1A1 (0.41) | ADORA2BKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL19207491 | 0.82 | CSNK2A1 (0.49) | TLR7ADORA2BADORA3ADORA2AADORA1 | |
| SCHEMBL19254588 | 0.80 | HDAC3 (0.47) | TLR7ADORA2BADORA3ADORA2AADORA1 | |
| SCHEMBL19207635 | 0.75 | HDAC3 (0.60) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL19207423 | 0.74 | CSNK2A1 (0.49) | TLR7ADORA2BADORA3ADORA2AADORA1 | |
| SCHEMBL19207434 | 0.72 | CSNK2A1 (0.47) | TLR7KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL19254333 | 0.72 | CSNK2A1 (0.47) | TLR7KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL19207433 | 0.72 | CSNK2A1 (0.41) | KDM4EMAPTHSD17B10 | |
| SCHEMBL19207408 | 0.65 | THRB (0.49) | KDM4EALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10765681-B2 | Purine compounds possessing anticancer activity | ACADEMIA SINICA (TW) | 2020-09-08 | — | — | US | disclosed |
| US-20180369249-A1 | PURINE COMPOUNDS POSSESSING ANTICANCER ACTIVITY | ACADEMIA SINICA (TW) | 2018-12-27 | — | — | US | disclosed |
| WO-2017136689-A1 | PURINE COMPOUNDS POSSESSING ANTICANCER ACTIVITY | ACADEMIA SINICA (TW) | 2017-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180369249-A1 | PURINE COMPOUNDS POSSESSING ANTICANCER ACTIVITY | NTPCR, PNP, NUDT1 | TLR7 1697/4885TLR8 2844/4885ADORA2B 106/4885 |
| US-10765681-B2 | Purine compounds possessing anticancer activity | NTPCR, PNP, NUDT1 | TLR7 1697/4885TLR8 2844/4885ADORA2B 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.